CollPlant and United Therapeutics Corporation have recently announced their licensing, development, and commercialization agreement for 3D Bioprinted Lung Transplants. Combining United Therapeutics’ organ manufacturing and regenerative medicine capabilities through Lung Biotechnology PBC with CollPlant’s BioInk and proprietary recombinant human collagen (rhCollagen) technology, CollPlant will receive an initial upfront payment of $5 million to kick start the project.